Why is the Fed hesitant on December rate cuts?
How did Nvidia calm AI bubble fears?
Why is Verizon cutting 13,000 jobs now?
What drove Walmart’s rising e-commerce sales?
How will Trump’s AI regulation affect states?
Why is Japan increasing foreign residency fees?
What impacts do rare-earth export shifts have?
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
benzinga.com/news/health-care/25/11/48957826/mercks-investigational-two-drug-regime-matches-gileads-three-drug-tablet-for-hiv-treatment
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment…
This story appeared on benzinga.com, 2025-11-19 18:23:40.